Pfizer CEO says 2023 will be ‘transition year’ as it sees drop in COVID sales
Pfizer Inc on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment for 2023, intensifying investor concerns over demand for the products.